<DOC>
	<DOCNO>NCT01442376</DOCNO>
	<brief_summary>The primary objective evaluate efficacy two different dos IV palonosetron prevention chemotherapy induce nausea vomit MEC HEC patient 120 hour start chemotherapy single repeat chemotherapy cycle . The secondary objective evaluate safety tolerability IV palonosetron pediatric patient evaluate pharmacokinetics IV palonosetron subset pediatric CINV patient .</brief_summary>
	<brief_title>Efficacy Safety Palonosetron Intravenous Prevention Chemotherapy Induced Nausea Vomiting Pediatric Patients</brief_title>
	<detailed_description>For neonate ( &lt; 28 day , full term ) open-label sub-study conduct assess exposure tolerability age group escalate dos palonosetron , start 3 mcg/kg first three neonate include study . If dose show safe well tolerate follow three neonate treat dose 10 mcg/kg . If also dose safe well tolerate , follow three neonate treat dose 20 mcg/kg . If last dose also show safe well tolerate , follow neonate randomize main study .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Written inform consent sign parent ( ) /legal guardian pediatric patient compliance local law regulation . In addition sign child 's assent form accord local requirement Male female outpatient neonate ( full term ) &lt; 17 year time randomization Patient weight least 3.2 kg Histologically , and/or cytologically ( image case brain tumor ) confirm malignant disease Naïve nonnaïve chemotherapy Scheduled eligible receive least one moderately highly emetogenic chemotherapeutic agent Study Day 1 For patient age ≥ 10 year &lt; 17 year : ECOG PS ≤ 2 For patient know hepatic impairment : Investigator 's opinion impairment jeopardize patient 's safety study For patient know renal impairment : Investigator 's opinion impairment jeopardize patient 's safety study For patient know history predisposition cardiac abnormality : Investigator 's opinion history/predisposition jeopardize patient 's safety study For patient know clinically relevant abnormal laboratory value : Investigator 's opinion abnormality jeopardize patient 's safety study Fertile patient ( male female ) must use reliable contraceptive measure Female patient attain menarche must negative pregnancy test screen visit ( Visit 1 ) study treatment visit ( Visit 2 ) Lactating pregnant female patient Patient receive total body irradiation , upper abdomen radiotherapy , radiotherapy cranium , craniospinal region pelvis within 1 week prior study entry ( screen ) Scheduled receive concomitant total body irradiation , radiotherapy upper abdomen , low thorax region , cranium/craniospinal region 24 hour study drug administration Known history allergy component contraindication 5HT3 receptor antagonist Active infection Uncontrolled medical condition Marked baseline prolongation QTc interval [ QTcB QTcF &gt; 460 msec ] ECG assessment screen . For purpose , assessment rely automatic interpretation ECG machine Patient suffer ongoing vomit organic etiology ( include patient history gastric outlet obstruction intestinal obstruction due adhesion volvulus ) patient hydrocephalus Patient experience vomit , retch , nausea within 24 hour prior administration study drug Patient receive drug potential antiemetic effect within 24 hour prior administration study treatment , include limited : NK1 receptor antagonist ( e.g . aprepitant ) 5HT3 antagonist ( e.g. , ondansetron , granisetron , dolasetron ) ; Phenothiazines ( e.g. , perphenazine , prochlorperazine , promethazine , fluphenazine , chlorpromazine , thiethylperazine ) ; Butyrophenones ( e.g. , droperidol , haloperidol ) ; Benzamides ( e.g. , metoclopramide , alizapride ) ; Corticosteroids ( e.g. , prednisone , methylprednisolone ; except inhaled steroid respiratory disorder topical steroid skin disease dos ≤ 10 mg prednisone daily equivalent ) ; Corticosteroids foresee chemotherapy regimen reduce intracranial pressure allow . According guidelines1,2 , patient receive also dexamethasone comedication accordance standard clinical practice deem appropriate Investigator . Dimenhydrinate ; Hydroxyzine ; Domperidone ; Lorazepam ; Cyclizine ; Cannabinoids ; Scopolamine ; Trimethobenzamide HCl ; Meclizine hydrochloride ; Pseudoephedrine HCl ; Over Counter ( OTC ) antiemetic , OTC cold OTC allergy medication ; Herbal preparation contain ephedra ginger . Patient age ≤ 6 year receive investigational drug ( defined medication marketing authorization grant age group indication ) within 90 day prior Day 1 , patient age &gt; 6 year receive investigational drug within 30 day prior Day 1 expect receive investigational drug prior study completion Patient participate previous trial palonosetron</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Prevention Chemotherapy-Induced Nausea Vomiting</keyword>
	<keyword>Palonosetron</keyword>
	<keyword>Ondansetron</keyword>
	<keyword>Pediatric</keyword>
</DOC>